Vertex Pharmaceuticals Incorporated (VRTX)
Automate Your Wheel Strategy on VRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VRTX
- Rev/Share 43.2063
- Book/Share 64.2129
- PB 6.9531
- Debt/Equity 0.1
- CurrentRatio 2.6456
- ROIC -0.128
- MktCap 114654724560.0
- FreeCF/Share -4.8968
- PFCF -91.1405
- PE -115.9882
- Debt/Assets 0.0721
- DivYield 0
- ROE -0.0625
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VRTX | Wolfe Research | Outperform | Peer Perform | -- | -- | May 7, 2025 |
| Downgrade | VRTX | Leerink Partners | Outperform | Market Perform | -- | $503 | May 6, 2025 |
| Resumed | VRTX | Cantor Fitzgerald | -- | Overweight | -- | $535 | April 22, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | $408 | $424 | Feb. 12, 2025 |
| Upgrade | VRTX | Canaccord Genuity | Sell | Hold | -- | -- | Feb. 11, 2025 |
| Downgrade | VRTX | Wells Fargo | Overweight | Equal Weight | -- | $460 | Jan. 30, 2025 |
| Reiterated | VRTX | H.C. Wainwright | -- | Buy | $600 | $535 | Dec. 20, 2024 |
| Downgrade | VRTX | Oppenheimer | Outperform | Perform | -- | -- | Dec. 19, 2024 |
| Upgrade | VRTX | Jefferies | Hold | Buy | $500 | $550 | Dec. 9, 2024 |
| Initiation | VRTX | Scotiabank | -- | Sector Perform | -- | -- | Oct. 16, 2024 |
News
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Published: March 24, 2025 by: CNBC Television
Sentiment: Positive
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
Read More
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and Alyftrek launch progress.
Read More
Final Trades: Netflix, Meta, Vertex, Interactive Brokers and the COWZ
Published: March 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ET Company Participants Charlie Wagner - CFO and COO David Altshuler - Chief Scientific Officer Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger Great. Well thanks very much, everyone, for joining us for our next session with Vertex.
Read More
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Positive
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company's 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Published: February 21, 2025 by: The Motley Fool
Sentiment: Positive
Looking for a good area in which to invest? Consider the healthcare sector.
Read More
GILD or VRTX: Which Is the Better Value Stock Right Now?
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
3 Stocks That Could Trounce the Market in 2025
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
Published: February 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Read More
The Ultimate Healthcare Stock to Buy With $500 Right Now
Published: February 14, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.
Read More
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Published: February 14, 2025 by: The Motley Fool
Sentiment: Positive
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.
Read More
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Read More
Calls of the Day: Charles Schwab, Vertex Pharma and Transocean
Published: February 11, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.
Read More
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - President and Chief Executive Office Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Evan Seigerman - BMO Capital Markets Jessica Fye - JPMorgan Geoff Meacham - Citibank Michael Yee - Jefferies William Pickering - Bernstein Liisa Bayko - Evercore ISI Phil Nadeau - TD Cowen Eliana Merle - UBS Tazeen Ahmad - Bank of America Dave Risinger - Leerink …
Read More
Markets Steady, Positive; Q4 Earnings Keep Rolling
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Indexes mostly shrugged off +25% steel tariffs announced by President Trump; VRTX, LSCC report for Q4.
Read More
Vertex's Revenue Surges but EPS Slips
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion.
Read More
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Published: February 10, 2025 by: Investopedia
Sentiment: Positive
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
About Vertex Pharmaceuticals Incorporated (VRTX)
- IPO Date 1991-07-24
- Website https://www.vrtx.com
- Industry Biotechnology
- CEO Dr. Reshma Kewalramani FASN, M.D.
- Employees 6100